OncoSec’s defense of weak preliminary Tavo data for PD-1 resistant melanoma can’t stop a rout
OncoSec execs may be regretting their decision to release preliminary Phase IIb data on the combination of Merck’s Keytruda and their big pipeline play Tavo.
Researchers are reporting results for only 9 patients with metastatic melanoma at 12 weeks, and came out in a defensive posture for the 2 partial responses they tracked at that stage in KEYNOTE-695. All of the patients had seen their cancer progress after treatment with Opdivo or Keytruda in the lead study at OncoSec.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.